AUC

:   area under the curve

CI

:   confidence interval

DAVID

:   Database for Annotation, Visualization and Integrated Discovery

GO

:   Gene Ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

LR

:   likelihood ratio

LUAD

:   lung adenocarcinoma

LUSC

:   lung squamous cell carcinoma

miRNA

:   microRNA

NSCLC

:   non‐small cell lung cancer

OR

:   odds ratio

PPI

:   protein--protein interaction

PT

:   paracancer tissue

ROC

:   receiver operating characteristic

SMD

:   standard mean difference

SROC

:   summary receiver operating characteristic

TCGA

:   The Cancer Genome Atlas

TNM

:   tumor, node and metastasis

Lung cancer is one of the most severe malignancies threatening human health. According to the latest cancer statistics published in 2017, it remained the main cause of death in both men and women [1](#feb412354-bib-0001){ref-type="ref"}. In China, lung cancer was also the most frequent cancer and the top cause of cancer death in 2015 [2](#feb412354-bib-0002){ref-type="ref"}. The latest data provided by The National Central Cancer Registry of China revealed that non‐small cell lung cancer (NSCLC) accounted for \~80--85% of newly diagnosed cases of lung cancer, and the 5‐year survival rate of NSCLC was approximately 11% [3](#feb412354-bib-0003){ref-type="ref"}. Currently, standard diagnostic approaches mainly include radiography, computed tomography, bronchial needle aspiration biopsy guided by ultrasound and detection of bronchial lavage tumor markers. Despite the advantages of these available diagnostic strategies, the lack of sufficient specificity and sensitivity creates a challenge for the identification of lung cancer at an early stage [4](#feb412354-bib-0004){ref-type="ref"}. Tumor biomarkers have attracted great attention in the research area of lung cancer, since this cancer\'s occurrence is a result of a long‐term process presenting with the change of a normal cell to a malignant one, which includes gradual genetic alterations [5](#feb412354-bib-0005){ref-type="ref"}. Many lung cancer‐related oncogenes, as well as tumor suppressors, have been identified, and aberrations of several signaling pathways have also been discovered [6](#feb412354-bib-0006){ref-type="ref"}. Nevertheless, the specific molecular mechanism for the occurrence of lung cancer still remains uncertain. Recent studies have confirmed the correlation between lung cancer and non‐coding RNAs, among which microRNAs (miRNAs) account for a large proportion.

miRNAs are a type of naturally occurring, small non‐coding RNA molecule with approximately 21--25 nucleotides [7](#feb412354-bib-0007){ref-type="ref"}. Recently, an increasing amount of research has shown that abnormally expressed miRNAs participating in the incidence and development of malignant tumors may become a new type of tumor marker [8](#feb412354-bib-0008){ref-type="ref"}. miRNAs can control numerous biological pathways driving tumor behavior by targeting and controlling gene expression in lung cancer [9](#feb412354-bib-0009){ref-type="ref"}, [10](#feb412354-bib-0010){ref-type="ref"}. The characteristics of miRNAs modulating gene networks and corresponding biological pathways have provided new hope for diagnosing and guiding novel therapeutic decisions for lung cancer patients [10](#feb412354-bib-0010){ref-type="ref"}. However, numerous miRNAs need to be identified and their potential molecular mechanisms still remain to be further determined.

miR‐193a‐3p is one of the cancer‐related miRNAs. It has been found that up‐regulated miR‐193a‐3p functions as an oncogene in esophageal squamous cell carcinoma, modulating proliferation, migration and apoptosis [11](#feb412354-bib-0011){ref-type="ref"}. Aberrant regulation of miR‐193a‐3p has also been found in the development of other types of cancer, such as prostate cancer, breast cancer, head and neck squamous cell carcinomas, and colorectal cancer [12](#feb412354-bib-0012){ref-type="ref"}, [13](#feb412354-bib-0013){ref-type="ref"}, [14](#feb412354-bib-0014){ref-type="ref"}, [15](#feb412354-bib-0015){ref-type="ref"}. Previously, we reported that miR‐193a‐3p might be a tumor suppressor in hepatocellular carcinoma. Besides, the expression level of serum miR‐193a‐3p combined with alpha‐fetoprotein and ultrasound could assist in the diagnosis of hepatocellular carcinoma at an early stage [16](#feb412354-bib-0016){ref-type="ref"}. Our previous work using quantitative real‐time polymerase chain reaction also demonstrated that the miR‐193a‐3p level in NSCLC tissue samples was significantly down‐regulated compared with that in non‐tumorous lung tissues [17](#feb412354-bib-0017){ref-type="ref"}. Several other reports also determined the level of miR‐193a‐3p in lung cancer tissues, but the sample size varied and the results were inconsistent. However, no study has mined the public high‐throughput data of RNA‐sequencing and microarray to explore the clinical role of miR‐193a‐3p in lung cancer.

The function and molecular mechanisms of miR‐193a‐3p have been explored in a few diseases. For instance, in human osteosarcoma, miR‐193a‐3p functioned as a suppressor by suppressing the signaling pathway of Rab27B and serine racemase [18](#feb412354-bib-0018){ref-type="ref"}, [19](#feb412354-bib-0019){ref-type="ref"}. Similarly, the suppressive influence of miR‐193a‐3p on growth was related to the reduction of *MCL1* expression in malignant pleural mesothelioma [20](#feb412354-bib-0020){ref-type="ref"}. In NSCLC, only three targets have been confirmed, including *ERBB4*,*S6K2* and *KRas* [19](#feb412354-bib-0019){ref-type="ref"}, [21](#feb412354-bib-0021){ref-type="ref"}, [22](#feb412354-bib-0022){ref-type="ref"}. Nevertheless, other specific regulatory mechanisms of miR‐193a‐3p in lung cancer are still uncertain, due to the diversity of target genes regulated by a single miRNA. Hence, the objective of the present study was to evaluate the association between miR‐193a‐3p level and the development of NSCLC using public high‐throughput data including RNA‐sequencing, microarray and all available published documents. Further, we also explored the potential signaling of miR‐193a‐3p in the carcinogenesis of NSCLC via *in silico* approaches, such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein--protein interaction (PPI) pathway analyses.

Materials and methods {#feb412354-sec-0002}
=====================

Data acquisition in GEO and ArrayExpress datasets {#feb412354-sec-0003}
-------------------------------------------------

### Search strategy and inclusion criteria {#feb412354-sec-0004}

We searched the NSCLC‐related miRNA microarray or RNA‐sequencing data from the National Center of Biotechnology Information (NCBI) Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) and ArrayExpress to 1 July 2017.

The search strategy was as follows: (lung OR pulmonary OR respiratory OR bronchi OR bronchioles OR alveoli OR pneumocytes OR 'air way') AND (cancer OR carcinoma OR tumor OR neoplas\* OR malignan\* OR adenocarcinoma) AND (MicroRNA OR miRNA OR 'Micro RNA' OR 'Small Temporal RNA' OR 'non‐coding RNA' OR ncRNA OR 'small RNA').

The inclusion criteria of eligible datasets were as follows. Firstly, the experimental group should be NSCLC patients and the control group should be non‐cancerous individuals. Secondly, the minimum number of samples for each group should be 30. Thirdly, the raw miRNAs expression data from profiling of experimental and control groups should be available or calculable, which provided the expression level of miR‐193a‐3p. Fourthly, only human samples were included. Fifthly, both tissue and peripheral blood samples from NSCLC were included.

### Statistical analysis {#feb412354-sec-0005}

Firstly, the expression level of miR‐193a‐3p was extracted from each microarray. Student\'s paired or unpaired *t* test was used to assess the difference of miR‐193a‐3p level between different groups with [spss statistics]{.smallcaps} v. 23.0 (IBM Corp., Armonk, NY, USA). Receiver operating characteristic (ROC) curve analyses were used to assess the diagnostic significance of miR‐193a‐3p in NSCLC. *P* \< 0.05 was considered as statistically significant in the current study.

Secondly, a meta‐analysis with GEO and ArrayExpress data was performed with [stata v]{.smallcaps}. 12.0 (StataCorp, College Station, TX, USA) and the [metan]{.smallcaps} package. Continuous outcomes were presented as standard mean difference (SMD) with 95% confidence interval (CI), and effect sizes were pooled with a random or fixed‐effects model based on different conditions. Heterogeneity across studies was assessed with the chi‐square test of *Q* and the *I* ^2^ statistic. A *P* value \< 0.05 or *I* ^2^ \> 50% was considered heterogeneous. If so, the random‐effects model (the DerSimonian--Laird method) would be selected to calculate the summarized SMD. If not, the fixed‐effects model (the Mantel--Haenszel method) was preferred for the pooling process.

If heterogeneity was present, to further explain whether the pooled result was achieved due to one large study or a single study with an extremely divergent result, sensitivity analysis was applied to omit one study at a time. In addition, the potential publication bias was evaluated with Begg\'s and Egger\'s tests. If *P* \< 0.05, there would be publication bias.

Another approach, meta‐analysis with summary receiver operating characteristic (SROC), was further carried out to verify the expression level of miR‐193a‐3p in NSCLC cases. Further, diagnostic odds ratio analysis was executed to assess the diagnostic possibility of miR‐193a‐3p for NSCLC patients. Positive and negative likelihood ratios were also obtained to reflect the diagnostic value of miR‐193a‐3p.

Implication of miR‐193a‐3p expression in NSCLC based on The Cancer Genome Atlas data {#feb412354-sec-0006}
------------------------------------------------------------------------------------

The Cancer Genome Atlas (TCGA) only offered expression data of precursor miRNA; therefore, we extracted the miR‐193a expression data from lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. We also collected the clinical pathological parameters of the patients. The differences of miR‐193a between different groups were assessed as mentioned above. The association between miR‐193a expression and the clinicopathological features was determined using [spss statistics]{.smallcaps} 23.0.

Meta‐analysis of studies from literatures {#feb412354-sec-0007}
-----------------------------------------

PubMed, Web of Science, EMBASE, Science Direct, Wiley Online Library, Ovid, Cochrane Central Register of Controlled Trials, LILACs and Google Scholar, and the CNKI, VIP, CBM and WanFang databases were used to search for studies evaluating the clinical value of miR‐193a‐3p in NSCLC. Literature published up to April 2017 was retrieved. The search terms were the same as aforementioned for the GEO database. All eligible studies were included in line with the following criteria: (a) NSCLC patients should be affirmed pathologically; (b) the expression level of miR‐193a‐3p should be evaluated for NSCLC patients or mean and standard deviation (SD) should be provided; (c) the literature should be the most complete or recent if the same patient cohort was reported more than once by the same authors or research group; (d) it should be written in either Chinese or English in full text.

Meta‐analysis based on GEO and TCGA databases and literature {#feb412354-sec-0008}
------------------------------------------------------------

To obtain the comprehensive picture of the clinical role of miR‐193a‐3p in NSCLC, we combined all available data from GEO, TCGA and literature in the final meta‐analyses. Similar approaches were performed as aforementioned, including the calculation of SMD and SROC.

Potential function inquiry of miR‐193a‐3p in NSCLC {#feb412354-sec-0009}
==================================================

Identification of prospective target genes of miR‐193a‐3p {#feb412354-sec-0010}
---------------------------------------------------------

To gain possible target genes of miR‐193a‐3p, 12 online target gene prediction databases were used, namely miRBase, miRDB, miRWalk, RNA22, Targetscan, miR.org, Tarbase, mirTarBase, PicTar‐vet, Targetminer, PITA and PolymiRTS. Genes overlapping in more than five databases were collected as the 'prediction set' of miR‐193a‐3p target genes. At the same time, verified genes were gained from Tarbase, mirTarBase, miRWalk2.0, miRecords and literature.

In addition, we assessed the differentially expressed genes of LUAD and LUSC from TCGA. All datasets were processed and calculated for total read counts and reads per million values. The [edger]{.smallcaps} package was used to perform the statistical analysis. All the dysregulated genes of LUAD and LUSC were obtained for intersection elements. Finally, the overlap section of predicted target genes and the dysregulated ones from TCGA were collected for the following analysis.

Signaling pathway and gene network analyses {#feb412354-sec-0011}
-------------------------------------------

The potential target genes of miR‐193a‐3p achieved above were pooled for further GO and KEGG analyses with Database for Annotation, Visualization and Integrated Discovery (DAVID), which was applied to perform GO enrichment and KEGG pathway analysis. The predicted target genes were uploaded to DAVID, and only pathways with *P* \< 0.05 were considered to be statistically significant. The STRING database was utilized to construct the PPI network for the hub gene identification. Hub genes were regarded as the key target genes of miR‐193a‐3p in NSCLC. Associations among proteins were assessed by adopting a confidence score threshold of \> 0.4.

Results {#feb412354-sec-0012}
=======

Features of the included datasets from GEO and ArrayExpress {#feb412354-sec-0013}
-----------------------------------------------------------

Altogether, 19 eligible datasets were involved in the meta‐analysis, including [GSE17681](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17681) (Germany), [GSE27486](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27486) (USA), [GSE31586](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31586) (Germany), [GSE40738](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40738) (USA), [GSE46729](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46729) (USA), [GSE61741](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61741) (Germany), [GSE68951](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68951) (Germany), [GSE14936](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14936) (USA), [GSE16025](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16025) (USA), [GSE15008](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15008) (China), [GSE25508](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25508) (Finland), [GSE19945](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19945) (Japan), [GSE47525](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47525) (Netherlands), [GSE48414](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48414) (Norway), [GSE51853](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51853) (Japan), [GSE63805](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63805)\> (USA), GSE 72526 (Switzerland), [GSE74190](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74190) (China) and [GSE77380](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77380) (Japan).

The data for [GSE17681](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17681) (Germany), [GSE27486](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27486) (USA), [GSE31586](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31586) (Germany), [GSE40738](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40738) (USA) and [GSE61741](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61741) (Germany) were derived from peripheral blood, and the data for [GSE46729](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46729) and [GSE68951](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68951) were from serum and plasma, respectively. The data for [GSE14936](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14936) (USA), [GSE16025](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16025) (USA), [GSE15008](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15008) (China), [GSE25508](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25508) (Finland), [GSE19945](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19945) (Japan), [GSE47525](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47525) (Netherlands), [GSE48414](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48414) (Norway), [GSE51853](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51853) (Japan), [GSE63805](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63805) (USA), [GSE72526](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72526) (Switzerland), [GSE74190](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74190) (China) and [GSE77380](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77380) (Japan) were from NSCLC tissues.

In total, 453 cases of NSCLC patients and 476 normal controls were contained in blood samples, while 920 cases of NSCLC patients and 406 normal controls provided tissue samples (Table [1](#feb412354-tbl-0001){ref-type="table-wrap"}).

###### 

Characteristics of hsa‐miR‐193a‐3p expression profiling datasets included in the current meta‐analysis. NSCLC, non‐small cell lung carcinoma; SCLC, small cell lung carcinoma

  Series                                                                   Country       Sample type        Platform   Lung cancer types                               Sample of lung cancer patients   Sample of healthy controls   Citation (ref.)              Year
  ------------------------------------------------------------------------ ------------- ------------------ ---------- ----------------------------------------------- -------------------------------- ---------------------------- ---------------------------- ------
  [GSE61741](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE61741)   Germany       Peripheral blood   GPL9040    NSCLC                                           73                               94                           Keller A                     2014
  [GSE46729](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46729)   USA           Serum              GPL8786    NSCLC                                           24                               24                           Godrey A, *et al*.           2014
  [GSE40738](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE40738)   USA           Whole blood        GPL16016   NSCLC                                           82                               58                           Patnaik SK, *et al*.         2012
  [GSE27486](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27486)   USA           Whole blood        GPL11432   NSCLC[a](#feb412354-note-0001){ref-type="fn"}   22                               23                           Patnaik SK, *et al*.         2011
  [GSE68951](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68951)   Germany       Plasma             GPL16770   NSCLC                                           203                              12                           Leidinger P, *et al*.        2015
  [GSE17681](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17681)   Germany       Peripheral blood   GPL9040    NSCLC                                           17                               198                          Keller A, *et al*.           2009
  [GSE31568](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31568)   Germany       Peripheral blood   GPL9040    NSCLC                                           32                               67                           Keller A, *et al*.           2011
  [GSE14936](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14936)   USA           Tissue             GPL8879    NSCLC                                           27                               28                           Seike M, *et al*.            2009
  [GSE15008](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15008)   China         Tissue             GPL8176    NSCLC                                           182                              185                          Tan X, *et al*.              2010
  [GSE16025](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16025)   USA           Tissue             GPL5106    NSCLC                                           58                               5                            Raponi M, *et al*.           2009
  [GSE19945](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19945)   Japan         Tissue             GPL9948    NSCLC, SCLC                                     55                               8                            Ohba T, *et al*.             2013
  [GSE25508](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25508)   Finland       Tissue             GPL7731    NSCLC                                           26                               26                           Guled M, *et al*.            2011
  [GSE47525](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47525)   Netherlands   Tissue             GPL17222   NSCLC                                           18                               14                           van Jaarsveld MT, *et al*.   2013
  [GSE48414](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48414)   Norway        Tissue             GPL16770   NSCLC                                           154                              20                           Bjaanaes MM, *et al*.        2014
  [GSE51853](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51853)   Japan         Tissue             GPL7341    NSCLC                                           124                              5                            Arima C, *et al*.            2014
  [GSE63805](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63805)   USA           Tissue             GPL18410   NSCLC                                           32                               30                           Robles AI, *et al*.          2015
  [GSE72526](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72526)   Switzerland   Tissue             GPL20275   NSCLC                                           67                               18                           Gasparini P, *et al*.        2015
  [GSE74190](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74190)   China         Tissue             GPL19622   NSCLC                                           92                               44                           Jin Y, *et al*.              2015
  [GSE77380](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77380)   Japan         Tissue             GPL16770   NSCLC, SCLC                                     85                               23                           Yoshimoto T                  2016

Only adenocarcinomas were involved.

John Wiley & Sons, Ltd

Potential Diagnostic value of miR‐193a‐3p as a marker for NSCLC based on GEO and ArrayExpress {#feb412354-sec-0014}
---------------------------------------------------------------------------------------------

Firstly, the expression level of miR‐193a‐3p was extracted from each microarray. Student\'s paired or unpaired *t* test was used to assess the alteration of miR‐193a‐3p level between different groups with [spss statistics]{.smallcaps} 23.0. ROC curve analyses were used to assess the diagnostic significance of miR‐193a‐3p in NSCLC (Figs [1](#feb412354-fig-0001){ref-type="fig"} and [2](#feb412354-fig-0002){ref-type="fig"}). *P*  \< 0.05 was regarded as being statistically significant in the current study.

![Diagnostic value of miR‐193a‐3p expression in NSCLC patient samples. (A,C,E,G,I,K,M) Plot diagram of miR‐193a‐3p expression based on blood samples. (B,D,F,H,J,L,N)ROC curve of miR‐193a‐3p for diagnosis of NSCLC patients based on blood samples.](FEB4-8-94-g001){#feb412354-fig-0001}

![(A,C,E,G,I,K,M,O,Q,S,U,W) Plot diagram of miR‐193a‐3p expression based on tissue samples. (B,D,F,H,J,L,N,P,R,T,V,X) ROC curve of miR‐193a‐3p for diagnosis of NSCLC patients based on tissue samples.](FEB4-8-94-g002){#feb412354-fig-0002}

In the meta‐analysis of blood samples, the SMD ranged from −0.56 to 0.62 among the seven datasets (Fig. [3](#feb412354-fig-0003){ref-type="fig"}A). According to the result of the heterogeneity test, there was significant heterogeneity in these datasets (*P* = 0.045, *I* ^2^ = 53.5%). Thus, the expression level of blood miR‐193a‐3p between the NSCLC and normal controls was of no difference based on the random‐effects model (SMD = 0.03; 95% CI, −0.23 to 0.29).

![(A) Forest plot of the diagnostic value of blood miR‐193a‐3p in NSCLC. (B) Sensitivity analysis of blood miR‐193a‐3p in NSCLC. (C) Begg\'s funnel plot of blood miR‐193a‐3p in NSCLC; (D) Forest plot of the diagnostic value of blood miR‐193a‐3p in NSCLC after removing [GSE25486](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25486).](FEB4-8-94-g003){#feb412354-fig-0003}

According to sensitivity analysis, results indicated that study [GSE27486](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=) had the most negative influence on the summary SMD, which was consistently verified by Begg\'s funnel plot (Fig. [3](#feb412354-fig-0003){ref-type="fig"}B,C). Thus, study [GSE27486](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27486) was removed and the pooled SMD changed to 0.11 (95% CI, ‐0.12 to 0.34) as assessed by the random‐effects model, since the heterogeneity was still available (*P* = 0.161, *I* ^2^ = 36.9%, Fig. [3](#feb412354-fig-0003){ref-type="fig"}D).

In the meta‐analysis for tissue samples, the SMD ranged from ‐1.09 to 0.52 among the 12 datasets (Fig. [4](#feb412354-fig-0004){ref-type="fig"}A). According to the result of the heterogeneity test, there was significant heterogeneity in these datasets (*P* = 0.003, *I* ^2^ = 61.4%). Thus, the expression of tissue miR‐193a‐3p had no difference between the NSCLC and normal controls based on the random‐effects model (SMD = −0.20; 95% CI, −0.43 to 0.04).

![(A) Forest plot of the diagnostic value of tissue miR‐193a‐3p in NSCLC. (B) Sensitivity analysis of tissue miR‐193a‐3p in NSCLC. (C) Begg\'s funnel plot of tissue miR‐193a‐3p in NSCLC. (D) Forest plot of the diagnostic value of tissue miR‐193a‐3p in NSCLC after removing [GSE72526](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72526) and [GSE25508](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25508).](FEB4-8-94-g004){#feb412354-fig-0004}

The results of the sensitivity analysis indicated that the microarrays of [GSE72526](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72526) and [GSE25508](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25508) had the most negative influence on the summary SMD, which was consistently verified by Begg\'s funnel plot (Fig. [4](#feb412354-fig-0004){ref-type="fig"}B,C). Thus, the studies [GSE72526](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72526) and [GSE25508](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE25508) were removed and the pooled SMD changed to ‐0.33 (95% CI, ‐0.52 to ‐0.13) as assessed by the random‐effects model, since the heterogeneity was still present (*P* = 0.126, *I* ^2^ = 35.3%, Fig. [4](#feb412354-fig-0004){ref-type="fig"}D).

In addition, a SROC curve was plotted to show the diagnostic implications of miR‐193a‐3p in NSCLC. Firstly, in the samples of blood, the AUC of the SROC curve was 0.64 (Fig. [5](#feb412354-fig-0005){ref-type="fig"}A), which indicated that blood miR‐193a‐3p played a vital part in the early diagnosis of NSCLC. The pooled diagnostic odds ratio 2.36 (95% CI, 1.51--3.68, *P* = 0.226, Fig. [5](#feb412354-fig-0005){ref-type="fig"}B) also proved that the expression level of miR‐193a‐3p could distinguish patients from healthy people, which was verified by the pooled positive LR 1.40 (95% CI, 1.20--1.64, *P* = 0.502, Fig. [5](#feb412354-fig-0005){ref-type="fig"}C) and the pooled negative LR 0.66 (95% CI, 0.51--0.85, *P* = 0.046, Fig. [5](#feb412354-fig-0005){ref-type="fig"}D).

![(A) SROC curve of blood mir‐193a‐3p. The area under curve (AUC) of miR‐193a‐3p was 0.64 (95% CI, 0.60--0.68). (B) Diagnostic odds ratio of blood mir‐193a‐3p. (C) Positive LR of blood mir‐193a‐3p. (D) Negative LR of blood mir‐193a‐3p.](FEB4-8-94-g005){#feb412354-fig-0005}

In the samples of tissue, the AUC of the SROC curve was 0.79 (Fig. [6](#feb412354-fig-0006){ref-type="fig"}A), which indicated that the diagnostic ability of miR‐193a‐3p of tissue was more obvious than that of blood. The pooled diagnostic odds ratio 7.36 (95% CI, 3.54--15.27, *P* = 0.0018, Fig. [6](#feb412354-fig-0006){ref-type="fig"}B) also proved that the expression level of miR‐193a‐3p could distinguish patients from healthy people, which was verified by the pooled positive LR 3.04 (95% CI, 1.83--5.06, *P* \< 0.001, Fig. [6](#feb412354-fig-0006){ref-type="fig"}C) and the pooled negative LR 0.62 (95% CI, 0.54--0.70, *P* = 0.036, Fig. [6](#feb412354-fig-0006){ref-type="fig"}D).

![(A) SROC curve of tissue miR‐193a‐3p. The area under curve (AUC) of miR‐193a‐3p was 0.79 (95% CI, 0.76--0.83). (B) Diagnostic odds ratio of tissue miR‐193a‐3p. (C) Positive LR of tissue mir‐193a‐3p. (D) Negative LR of tissue miR‐193a‐3p.](FEB4-8-94-g006){#feb412354-fig-0006}

Characteristics of the patients with NSCLC from TCGA {#feb412354-sec-0015}
----------------------------------------------------

The correlation between the expression of miR‐193a and clinic pathological features in LUAD and LUSC tissues from TCGA were enumerated. Significant differences of miR‐193a expression level was found between lung cancer tissues and adjacent non‐cancerous ones in LUSC (*P* \< 0.001). The expression of miR‐193a was lower in lung cancer when compared with adjacent non‐cancerous lung. LUSC patients with a smoking habit (7.66 ± 0.79) had greater up‐expression of miR‐193a than those without the habit (7.45 ± 0.88, *P* = 0.023, Tables [2](#feb412354-tbl-0002){ref-type="table-wrap"}, [3](#feb412354-tbl-0003){ref-type="table-wrap"}, [4](#feb412354-tbl-0004){ref-type="table-wrap"}).

###### 

Relationship between the expression of miR‐193a and clinicopathological features in LUSC from TCGA (mean ± SD). For RPKM, Student\'s paired or unpaired *t* test was used

  Clinicopathological feature   *n*           miR‐193a relevant expression                                     
  ----------------------------- ------------- ------------------------------ --------------------- ----------- ----------
  Tissue                        Lung cancer   480                            7.525952 ± 0.865471   −4.948157   0.000004
  Adjacent non‐cancerous lung   45            7.888973 ± 0.414712                                              
  Age                           \> 65         185                            7.525579 ± 0.934945   0.050481    0.959761
  ≤ 65                          289           7.521452 ± 0.823057                                              
  Gender                        Male          347                            7.558295 ± 0.865309   1.637792    0.102140
  Female                        121           7.408978 ± 0.858448                                              
  Smoker                        Yes           130                            7.656648 ± 0.790222   2.277028    0.023243
  No                            332           7.454980 ± 0.880344                                              
  Clinical TNM stage            I and II      378                            7.521731 ± 0.846972   0.254974    0.798856
  III and IV                    88            7.495593 ± 0.944560                                              
  T                             T1 and T2     380                            7.484478 ± 0.855391   −1.834394   0.067233
  T3 and T4                     88            7.671741 ± 0.894978                                              
  N                             Yes           167                            7.421628 ± 0.937902   −1.652229   0.099505
  No                            295           7.565224 ± 0.821211                                              
  M                             Yes           6                              8.014767 ± 0.412640   1.541487    0.124018
  No                            382           7.458407 ± 0.881689                                              
  Tumor diameter (cm)           \> 0.9 cm     244                            7.496234 ± 0.783197   −0.689266   0.491016
  ≤ 0.9 cm                      230           7.551525 ± 0.949650                                              
  Location                      Central       136                            7.585938 ± 0.831344   −0.437418   0.662227
  Peripheral                    91            7.636411 ± 0.882065                                              
  Residual tumor                Yes           14                             7.627271 ± 0.597706   0.708142    0.479285
  No                            374           7.455612 ± 0.898980                                              
  Neoadjuvant treatment         Yes           6                              7.213383 ± 0.602037   −0.872681   0.383287
  No                            462           7.523668 ± 0.867740                                              
  Radiation therapy             Yes           41                             7.486063 ± 0.787671   −0.300110   0.764266
  No                            321           7.527955 ± 0.848168                                              
  Targeted molecular therapy    Yes           113                            7.451135 ± 0.797590   −0.998845   0.318533
  No                            253           7.545861 ± 0.855592                                              

John Wiley & Sons, Ltd

###### 

Univariate Cox regression analysis of characteristics in LUSC. B, B value is the regression coefficient and intercept (constant term); HR, hazard ratio; SE, standard error; Sig., *P* value

  Characteristic               B           SE         Wald statistic   df   Sig.       HR         95% CI
  ---------------------------- ----------- ---------- ---------------- ---- ---------- ---------- --------------------
  Clinical TNM stage           0.472445    0.175108   7.279332         1    0.006975   1.603911   1.137963--2.260643
  T                            0.547240    0.179851   9.258232         1    0.002344   1.728476   1.214992--2.458970
  N                            −0.254714   0.149093   2.918706         1    0.087558   0.775138   0.578723--1.038215
  M                            −0.273135   0.099921   7.472106         1    0.006266   0.760990   0.625643--0.925618
  Tumor diameter (cm)          0.117830    0.152824   0.594470         1    0.440696   1.125053   0.833852--1.517947
  Residual tumor               −0.181177   0.102099   3.148928         1    0.075977   0.834288   0.682982--1.019114
  Neoadjuvant treatment        −0.024768   0.583556   0.001801         1    0.966145   0.975536   0.310827--3.061734
  Radiation therapy            −0.133596   0.252688   0.279522         1    0.597014   0.874944   0.533202--1.435716
  Targeted molecular therapy   0.430070    0.209421   4.217337         1    0.040013   1.537365   1.019806--2.317588

John Wiley & Sons, Ltd

###### 

Multivariate Cox regression analysis of characteristics in LUSC. B, B value is the regression coefficient and intercept (constant term); HR, hazard ratio; SE, standard error; Sig., *P* value

  Characteristic               *B*         SE         Wald statistic   df   Sig.       HR         95% CI
  ---------------------------- ----------- ---------- ---------------- ---- ---------- ---------- --------------------
  T                            0.462151    0.244642   3.568666         1    0.058880   1.587485   0.982811--2.564185
  M                            −0.347973   0.104690   11.047946        1    0.000888   0.706118   0.575129--0.866941
  Clinical TNM stage           0.285211    0.250161   1.299845         1    0.254242   1.330043   0.814569--2.171718
  Targeted molecular therapy   0.497774    0.214111   5.404887         1    0.020080   1.645055   1.081257--2.502834

John Wiley & Sons, Ltd

For LUAD, patients with a smoking habit (7.58 ± 0.90) also had greater up‐expression of miR‐193a than those without it (7.36 ± 0.88, *P* = 0.020). Concerning the clinical tumor, node and metastasis (TNM) stage of LUAD, the relative level of miR‐193a was remarkably higher in stage N than in other stages (7.5 ± 0.87, *P* = 0.023). Compared with a peripheral location (7.55 ± 0.98), the expression of miR‐193a was reduced in central locations in LUAD (7.21 ± 0.79, *P* = 0.021, Tables [5](#feb412354-tbl-0005){ref-type="table-wrap"}, [6](#feb412354-tbl-0006){ref-type="table-wrap"}, [7](#feb412354-tbl-0007){ref-type="table-wrap"}).

###### 

Relationship between the expression of miR‐193a and clinicopathological features in LUAD from TCGA (mean ± SD). For RPKM, Student\'s paired or unpaired *t* test was used

  Clinicopathological feature   *n*           miR‐193a relevant expression                                     
  ----------------------------- ------------- ------------------------------ --------------------- ----------- ----------
  Tissue                        Lung cancer   513                            7.214102 ± 0.787625   −1.918105   0.061056
  Adjacent non‐cancerous lung   46            7.548920 ± 0.981258                                              
  Age                           \> 65         256                            7.368675 ± 0.908801   −0.877582   0.380600
  ≤ 65                          236           7.438942 ± 0.863317                                              
  Gender                        Male          239                            7.423370 ± 0.945404   0.135752    0.892071
  Female                        274           7.412676 ± 0.838690                                              
  Smoker                        Yes           119                            7.579224 ± 0.899954   2.326100    0.020416
  No                            378           7.362792 ± 0.880509                                              
  Clinical TNM stage            I and II      398                            7.380446 ± 0.884425   −1.828929   0.068001
  III and IV                    108           7.555999 ± 0.885666                                              
  T                             T1 and T2     442                            7.391222 ± 0.887205   −1.350914   0.177327
  T3 and T4                     66            7.549444 ± 0.889854                                              
  N                             Yes           171                            7.540150 ± 0.872370   2.286925    0.022620
  No                            328           7.349028 ± 0.893038                                              
  M                             Yes           23                             7.426187 ± 1.201434   0.308948    0.757537
  No                            344           7.364119 ± 0.912881                                              
  Tumor diameter (cm)           \> 7.4 cm     197                            7.485256 ± 0.831706   0.188783    0.850369
  ≤ 7.4 cm                      165           7.467500 ± 0.957637                                              
  Location                      Central       61                             7.214102 ± 0.787625   −2.321373   0.021368
  Peripheral                    124           7.548920 ± 0.981258                                              
  Residual tumor                Yes           16                             7.590387 ± 0.851161   1.268497    0.205456
  No                            339           7.365456 ± 0.884371                                              
  Neoadjuvant treatment         Yes           3                              7.868600 ± 0.907847   0.882194    0.378088
  No                            508           7.414468 ± 0.888921                                              
  Radiation therapy             Yes           48                             7.590387 ± 0.851161   1.656416    0.098455
  No                            338           7.365456 ± 0.884371                                              
  Targeted molecular therapy    Yes           124                            7.459590 ± 0.858687   0.967914    0.333700
  No                            260           7.366328 ± 0.894127                                              

John Wiley & Sons, Ltd

###### 

Univariate Cox regression analysis of characteristics in LUAD. B, B value is the regression coefficient and intercept (constant term); HR, hazard ratio; SE, standard error; Sig., *P* value

  Characteristic               B           SE         Wald statistic   df   Sig.       HR         95% CI
  ---------------------------- ----------- ---------- ---------------- ---- ---------- ---------- --------------------
  Clinical TNM stage           0.983100    0.155107   40.172597        1    0.000000   2.672728   1.972092--3.622284
  T                            0.716035    0.198479   13.014856        1    0.000309   2.046304   1.386834--3.019368
  N                            −0.681987   0.119488   32.576217        1    0.000000   0.505612   0.400045--0.639036
  M                            0.022253    0.087000   0.065424         1    0.798120   1.022502   0.862204--1.212603
  Tumor diameter (cm)          0.053987    0.179151   0.090811         1    0.763148   1.055471   0.742938--1.499477
  Residual tumor               −1.354798   0.308974   19.226680        1    0.000012   0.257999   0.140805--0.472735
  Neoadjuvant treatment        −0.567799   0.273796   4.300646         1    0.038098   0.566772   0.331400--0.969313
  Radiation therapy            −0.727292   0.219748   10.953925        1    0.000934   0.483216   0.314117--0.743345
  Targeted molecular therapy   −0.363251   0.186343   3.800016         1    0.051252   0.695412   0.482643--1.001977

John Wiley & Sons, Ltd

###### 

Multivariate Cox regression analysis of characteristics in LUAD. B, B value is the regression coefficient and intercept (constant term); HR, hazard ratio; SE, standard error; Sig., *P* value

  Characteristic               B           SE         Wald statistic   df   Sig.       HR         95% CI
  ---------------------------- ----------- ---------- ---------------- ---- ---------- ---------- --------------------
  T                            0.576365    0.295382   3.807376         1    0.051027   1.779558   0.997429--3.174988
  N                            −0.431418   0.207871   4.307350         1    0.037948   0.649587   0.432213--0.976287
  Clinical TNM stage           0.586918    0.207871   5.695250         1    0.017011   1.798437   1.110592--2.912299
  Residual tumor               −0.921665   0.408787   5.083375         1    0.024156   0.397856   0.178552--0.886515
  Neoadjuvant treatment        −2.635720   0.776167   11.531550        1    0.000684   0.071667   0.015655--0.328092
  Targeted molecular therapy   0.341323    0.269954   1.598646         1    0.206095   1.406808   0.828800--2.387921
  Radiation therapy            −0.684721   0.307561   4.956402         1    0.025994   0.504231   0.275952--0.921351

John Wiley & Sons, Ltd

However, no obvious association was observed between miR‐193a level and other clinicopathological features.

Information from studies from literature {#feb412354-sec-0016}
----------------------------------------

A total of 17 documents were retrieved, but only one of them met our criteria. Therefore, a meta‐analysis of studies could not be performed. The expression level of miR‐193a‐3p of NSCLC was prominently up‐regulated over that of adjacent non‐cancerous lung tissues (*P* \< 0.001) [17](#feb412354-bib-0017){ref-type="ref"}.

Target gene aggregation of miR‐193a‐3p {#feb412354-sec-0017}
--------------------------------------

A total of 512 genes were derived from miRWalk2.0, Tarbase, miRTarbase and miRecords, which were validated by qPCR, western blot or luciferase assay. Twelve online databases were used for the prediction and a total of 2586 targets genes overlapped in at least five databases were obtained. In addition, together with the extracted genes from the literature, we collected a total of 3121 predicted target genes.

From TCGA, 6138 up‐regulated genes in LUAD and LUSC were obtained. Finally, bioinformatics analyses were performed on the 379 overlapping sets of these genes.

GO and pathway enrichment analyses {#feb412354-sec-0018}
----------------------------------

According to the target‐GO analysis in DAVID, genes were highly concentrated in the biological processes of neurotransmitter transport, skeletal system development, ion transport, etc. (*P* \< 0.005, Fig. [7](#feb412354-fig-0007){ref-type="fig"}A), in the cellular components of integral to organelle membrane, intrinsic to organelle membrane, chromosomal part, etc. (*P* \< 0.05, Fig. [7](#feb412354-fig-0007){ref-type="fig"}B), and in the molecular functions of transcription factor activity, sequence‐specific DNA binding, leukotriene‐B4 20‐monooxygenase activity, etc. (*P* \< 0.05 Fig. [7](#feb412354-fig-0007){ref-type="fig"}C). In KEGG pathway analysis, target genes mainly gathered at pathways of cell cycle (*P* \< 0.05, Fig. [7](#feb412354-fig-0007){ref-type="fig"}D). In addition, we conducted protein--protein interaction (PPI) by STRING 10.0 to find the hub genes of mir‐193a‐3p. *E2F3*,*CDC6*,*AURKA*,*CHEK1*,*H2AFX*,*CDC25A* and *MYCN* were obtained (Figs [8](#feb412354-fig-0008){ref-type="fig"} and [9](#feb412354-fig-0009){ref-type="fig"}).

![Enriched Gene Ontology (GO) items of overlapping target genes of miR‐193a‐3p. (A) Pathways of biological processes (BP). (B) Pathways of cellular components (CC). (C) Network analysis of molecular function (MF). (D) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of miR‐193a‐3p target genes. The lengths of the bars represent the number of overlapping genes in GO and KEGG. AT, Oligo (A) and oligo (T) tracts of DNA; ECM, extracellular matrix.](FEB4-8-94-g007){#feb412354-fig-0007}

![Protein--protein interaction network of all 379 potential genes targeted by miR‐193a‐3p in NSCLC.](FEB4-8-94-g008){#feb412354-fig-0008}

![The top seven hub genes of miR‐193a‐3p with the largest number of connections in the protein--protein interaction target gene network.](FEB4-8-94-g009){#feb412354-fig-0009}

Discussion {#feb412354-sec-0019}
==========

miRNAs have the potential to function as steady and reproducible biomarkers for different solid malignant tumors, especially NSCLC [23](#feb412354-bib-0023){ref-type="ref"}, [24](#feb412354-bib-0024){ref-type="ref"}. The methylation of the mir‐193a gene has an indirect effect on the expression level of the target gene [25](#feb412354-bib-0025){ref-type="ref"}, [26](#feb412354-bib-0026){ref-type="ref"}, [27](#feb412354-bib-0027){ref-type="ref"}. In the oral squamous cell carcinoma, the miR‐193a gene is hypermethylated and the expression of miR‐193a was frequently down‐regulated [26](#feb412354-bib-0026){ref-type="ref"}. Conversely, miR‐193a gene methylation silencing could reduce miR‐193a expression in some diseases, for example acute myeloid leukemia and NSCLC [27](#feb412354-bib-0027){ref-type="ref"}, [28](#feb412354-bib-0028){ref-type="ref"}. Downregulation of the miR‐193a level in NSCLC tissues was reported by Chen *et al*. [29](#feb412354-bib-0029){ref-type="ref"}. In addition, our previous study found that the miR‐193a‐3p level was reduced in NSCLC tissues [17](#feb412354-bib-0017){ref-type="ref"}. In the current study, we studied the miR‐193a expression of NSCLC patients from TCGA and their corresponding paracancer tissue (PT). We found lower expression of miR‐193a in NSCLC tissues, in comparison with non‐cancerous controls, which confirmed the findings of Chen *et al*. [29](#feb412354-bib-0029){ref-type="ref"}. The relevant level of miR‐193a in LUAD was predominantly down‐regulated compared with that of the PT (*P* \< 0.001). Additionally, the relevant level of miR‐193a in LUSC was also less than that of the PT (*P* = 0.0056). The additional ROC curve demonstrated that miR‐193a had a diagnostic value for NSCLC, especially for LUAD. Thus, we were strongly convinced that miR‐193a could be a tumor‐suppressive predictor in NSCLC.

Since few studies have concentrated on the correlation between the expression of miR‐193a and clinic pathological features of NSCLC, we recruited patients to investigate the correlation between the expression of miR‐193a and clinicopathological features in LUAD and LUSC from TCGA. Firstly, there was a significant alteration of relevant miR‐193a expression between lung cancer and adjacent non‐cancerous lung. miR‐193a was down‐regulated in lung cancer compared with PT, which suggested its role in diagnosis. Secondly, the smoking habit was the common risk factor for LUAD and LUSC. However, there was a significant difference between miR‐193a and location and clinical TNM stage in LUAD. Tumors located in central parts expressed lower miR‐193a than those in peripheral parts. As for clinical TNM stage, miR‐193a was expressed at high levels in LUAD patients whose tumors were in stage N. These two indexes indicated poor prognosis and metastasis of LUAD. As for the discrepancy of miR‐193a expression in LUSC and LUAD, the highly expressed miR‐193a in the peripheral location and stage N of LUAD might be due to tumor cell differentiation. The exact mechanism needs further investigation.

miR‐193a‐3p is a member in the miR‐193a family. Nonetheless, information for miR‐193a‐3p is inadequate and its molecular function and mechanism in early diagnosis remain unidentified. No specific blood miRNA has been verified as a biomarker in the clinic for the early screening of NSCLC. Only two studies have explored the diagnostic value of miR‐193a‐3p, in hepatocellular carcinoma and colorectal cancer [15](#feb412354-bib-0015){ref-type="ref"}, [30](#feb412354-bib-0030){ref-type="ref"}. miR‐193a‐3p attracted our attention and in the present study we attempted to investigate the potential value of miR‐193a‐3p in early screening of NSCLC based on microarray databases, and to further explore its prospective relevant pathways via bioinformatics analysis.

In the meta‐analysis, a total of seven blood miR‐193a‐3p microarray datasets were involved, including 453 NSCLC patients and 297 healthy controls. The random effects model showed that significant inconsistency of miR‐193a‐3p expression was noticeable between NSCLC patients and healthy controls, since the AUC of the SROC curve was 0.64, which indicated a diagnostic value of blood miR‐193a‐3p in NSCLC compared with non‐cancerous controls.

Since we found a significantly lower miR‐193a‐3p level in NSCLC tissues, down‐regulation of miR‐193a‐3p also played a vital role in the prognosis of NLCLC [17](#feb412354-bib-0017){ref-type="ref"}. In the following study, we attempted to probe the probable value for tissue miR‐193a‐3p. In sum, we studied 12 tissue miR‐193a‐3p microarray datasets including 920 NSCLC patients and 406 healthy controls. The pooled diagnostic odds ratio was 7.36 (95% CI, 3.54--15.27, *P* = 0.0018). In addition, the AUC of the SROC curve was 0.79, which suggested that tissue miR‐193a‐3p had a reliable diagnostic value for NSCLC. Thus, we were strongly convinced that tissue miR‐193a‐3p was a tumor‐suppressive predictor in NSCLC. However, the diagnostic value of tissue miR‐193a‐3p still requires more studies to confirm this.

Concerning the molecular mechanism of miR‐193a‐3p in NSCLC, several reports have stated the function and molecular mechanism. miR‐193a‐3p could inhibit the metastasis of lung cancer cells by modulating the expression of cancer‐related proteins [31](#feb412354-bib-0031){ref-type="ref"}. It could also overpower the metastasis of human NSCLC by suppressing the Erb‐B2 Receptor Tyrosine Kinase 4 (ERBB4)/S6 kinase 2 (S6K2) signaling pathway [19](#feb412354-bib-0019){ref-type="ref"}. In addition, our previous study showed that astrocyte elevatedgene‐1 (AEG‐1) had the potential to be one target of miR‐193a‐3p [4](#feb412354-bib-0004){ref-type="ref"}. Since bioinformatics analysis might help in understanding the potential molecular mechanism of miR‐193a‐3p in the carcinogenesis and progression of NSCLC, we performed *in silico* predictions to gather all prospective target genes. Finally, we combined the validated genes and prediction genes together and achieved hub genes for miR‐193a‐3p. The GO and KEGG pathway analyses revealed that miR‐193a‐3p could be related to several key signaling pathways of NSCLC, such as modulation of apoptosis and modulation of programmed cell death in biological processes; organelle lumen, membrane‐enclosed lumen and intracellular organelle lumen in cellular components; identical protein binding, enzyme binding and transcription factor binding activities in molecular functions. Also, several vital pathways were illustrated by KEGG enrichment analysis, including pathways of cancer and focal adhesion signaling pathways. PPI showed the hub genes of mir‐193a‐3p, including *E2F3*,*CDC6*,*CHEK1*,*H2AFX*,*CDC25A*,*MYCN* and *AURKA*.

In view of the results we had achieved, we consulted literature to verify our findings. *E2F3* mRNA levels were significantly higher in lung cancer patients in comparison with non‐cancerous lung tissues and its overexpression was related to poor prognosis [32](#feb412354-bib-0032){ref-type="ref"}, [33](#feb412354-bib-0033){ref-type="ref"}. Also, *CDC6* has been confirmed to be linked to DNA replication to regulate the occurrence and development of lung tumor [34](#feb412354-bib-0034){ref-type="ref"}, [35](#feb412354-bib-0035){ref-type="ref"}. Overexpression of *CHEK1* in lung cancers was related to poor overall survival [36](#feb412354-bib-0036){ref-type="ref"}. An increase in *CDC25A* expression by means of a decrease in miR‐184 promoted cell invasive capacity [37](#feb412354-bib-0037){ref-type="ref"}. *MYCN* was found to be overexpressed in NSCLC, which was positively related to a more invasive tumor phenotype and poorer outcome [38](#feb412354-bib-0038){ref-type="ref"}. *AURKA* functioned as an oncogene, and its low expression level inhibited tumor cell proliferation, promoted apoptosis and hindered cell cycle development in NSCLC [39](#feb412354-bib-0039){ref-type="ref"}, [40](#feb412354-bib-0040){ref-type="ref"}.

However, there are some limitations to the current study. Firstly, the sample size in our study was still small, which would weaken the conclusion of the impact of miR‐193a‐3p in NSCLC patients. Secondly, the small sample size restricted the reliability of the meta‐analysis. Further larger studies should be conducted to support the under‐expression of tissue miR‐193a‐3p expression in NSCLC. Thirdly, extra bias might be due to the limited regions involved in the current meta‐analysis, since the only blood mir‐193a‐3p datasets were from USA and Germany. Fourthly, the potential target genes were achieved via *in silico* prediction, and further validation will also be needed.

Overall, the current observations showed that significant down‐expression of tissue miR‐193a‐3p was detected in NSCLC patients, which indicated tissue miR‐193a‐3p detection might play an integral part in the early diagnosis of NSCLC compared with blood miR‐193a‐3p. Furthermore, the pathway analyses of the prospective target genes of miR‐193a‐3p revealed several key signaling pathways correlated with the incidence and worsening of NSCLC, including the hub genes, such as neuroactive ligand--receptor interaction, cell cycle, etc. Cohorts with larger sample sizes and further *in vitro* and *in vivo* studies are needed to determine the diagnostic value and relevant mechanism of tissue miR‐193a‐3p in NSCLC.
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